HOOKIPA PharmaHOOK 50 14-Day RSI is 48.27 as of Jul. 09, 2026. GuruFocus rates HOOK with a GF Score™ of 50/100. Among 1,419 Biotechnology companies, HOOKIPA Pharma ranks better than 54.47% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-09), HOOKIPA Pharma's 14-Day RSI is 48.27.
The industry rank for HOOKIPA Pharma's 14-Day RSI or its related term are showing as below:
HOOK's 14-Day RSI is ranked better than 54.47% of 1419
companies
in the Biotechnology industry
Industry Median: 48.75
vs HOOK: 48.27
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
HOOKIPA Pharma 14-Day RSI Related Terms
HOOK vs COCP, LNAI, CYCN: 14-Day RSI Comparison
For the Biotechnology subindustry, HOOKIPA Pharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOOKIPA Pharma 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where HOOKIPA Pharma's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOKIPA Pharma (HOOK) has a 14-Day RSI of 48.27 as of Jul. 09, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on HOOKIPA Pharma and its competitors. According to the industry distribution chart, HOOKIPA Pharma ranks #646 out of 1419 companies in the Biotechnology industry, placing it in the top 45.5%.
Is HOOKIPA Pharma's 14-Day RSI too high?
HOOKIPA Pharma's current 14-Day RSI is 48.27. The Biotechnology industry median 14-Day RSI is 48.75. HOOKIPA Pharma's value of 48.27 is 1% below this industry median. Based on the distribution chart, HOOKIPA Pharma ranks #646 out of 1419 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HOOKIPA Pharma has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's 14-Day RSI compare to COCP and LNAI?
According to the Biotechnology industry distribution chart, HOOKIPA Pharma ranks #646 out of 1419 companies for 14-Day RSI. This puts HOOKIPA Pharma in the upper half of its industry. The industry median 14-Day RSI is 48.75. HOOKIPA Pharma's value of 48.27 is 1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.75, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOOKIPA Pharma's current 14-Day RSI of 48.27 is 1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on HOOKIPA Pharma and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOOKIPA Pharma's current 14-Day RSI is 48.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
HOOKIPA Pharma (HOOK) has a current 14-Day RSI of 48.27. The current 14-Day RSI is 48.27 and 1% below the Biotechnology industry median of 48.75. HOOKIPA Pharma's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current 14-Day RSI is 48.27 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score
Get the complete analysis for HOOK
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOOK has been successfully added to your 